Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases Indian Medical PG Practice Questions and MCQs

Question 71: All of the following statements are true except?

A. Sucralfate should not be given with antacids.
B. Cimetidine inhibits the metabolism of Ketoconazole.
C. Omeprazole acts by inhibiting H+ K+ ATPase.
D. Ranitidine acts by inhibiting H1 receptors. (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Ranitidine acts by inhibiting H1 receptors.** **1. Why Option D is the correct answer (The False Statement):** Ranitidine is a competitive antagonist at **H2 receptors**, not H1 receptors. H2 receptors are located on the gastric parietal cells and are responsible for stimulating gastric acid secretion. In contrast, H1 receptors are primarily involved in allergic reactions and are found in smooth muscles, endothelium, and the central nervous system. Therefore, Ranitidine is used to treat peptic ulcers and GERD by reducing acid output. **2. Analysis of Incorrect Options (True Statements):** * **A. Sucralfate should not be given with antacids:** Sucralfate requires an **acidic pH (pH < 4)** to polymerize into a sticky paste that adheres to the ulcer base. Antacids raise the gastric pH, preventing this activation and rendering Sucralfate ineffective. * **B. Cimetidine inhibits the metabolism of Ketoconazole:** This is a nuanced point. Cimetidine is a potent **Cytochrome P450 (CYP450) enzyme inhibitor**, which can slow the metabolism of many drugs. Additionally, Ketoconazole requires an acidic environment for absorption; by reducing acidity, Cimetidine (and other H2 blockers) reduces Ketoconazole’s absorption. * **C. Omeprazole acts by inhibiting H+ K+ ATPase:** Omeprazole is a Proton Pump Inhibitor (PPI). It irreversibly binds to the **H+/K+ ATPase pump** (the "final common pathway" of acid secretion) in the parietal cell canaliculi. **3. Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** PPIs (like Omeprazole) are the DOC for Peptic Ulcer Disease, GERD, and Zollinger-Ellison Syndrome. * **Cimetidine Side Effects:** It has anti-androgenic effects (gynecomastia, loss of libido) and is the most notorious H2 blocker for drug-drug interactions due to CYP450 inhibition. * **Sucralfate Timing:** It should be taken on an empty stomach, 1 hour before meals.

Question 72: Which of the following laxatives lowers blood ammonia levels in hepatic encephalopathy?

A. Bisacodyl
B. Lactulose (Correct Answer)
C. Magnesium sulfate
D. Liquid paraffin

Explanation: **Explanation:** **Lactulose** is the correct answer because it is a non-absorbable disaccharide that acts as an **osmotic laxative** and a **colonic acidifier**. In the colon, bacteria ferment lactulose into low-molecular-weight organic acids (lactic and acetic acid). This process lowers the colonic pH, which facilitates two key mechanisms to treat hepatic encephalopathy: 1. **Ammonia Trapping:** The acidic environment converts diffusible ammonia ($NH_3$) into non-diffusible ammonium ions ($NH_4^+$), trapping it in the gut for excretion. 2. **Inhibition of Ammonia Production:** The lower pH inhibits urease-producing bacteria and reduces the absorption of nitrogenous toxins. **Analysis of Incorrect Options:** * **A. Bisacodyl:** A stimulant laxative that acts directly on the enteric neurons to increase peristalsis. It has no effect on ammonia metabolism. * **C. Magnesium Sulfate:** An osmotic laxative that retains water in the intestinal lumen. While it causes rapid bowel evacuation, it does not alter colonic pH or specifically lower blood ammonia. * **D. Liquid Paraffin:** A stool softener/lubricant that eases the passage of hard stools. It is not used in the management of hepatic encephalopathy. **High-Yield NEET-PG Pearls:** * **Drug of Choice:** Lactulose is the first-line treatment for both acute and chronic hepatic encephalopathy. * **Synergy:** It is often combined with **Rifaximin** (a non-absorbable antibiotic) for superior results in reducing ammonia-producing gut flora. * **Monitoring:** The therapeutic goal is to achieve **2–3 soft stools per day**. * **Other uses:** Lactulose is also used to treat portal-systemic encephalopathy and chronic constipation.

Question 73: A patient presents with Zollinger-Ellison syndrome due to gastrinoma, experiencing two bleeding ulcers and diarrhoea. Which drug irreversibly inhibits the H+/K+ ATPase in gastric parietal cells?

A. Cimetidine
B. Cisapride
C. Glycopyrrolate
D. Omeprazole (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Omeprazole** Omeprazole is a **Proton Pump Inhibitor (PPI)**. It is a prodrug that gets activated in the acidic environment of the canaliculi of gastric parietal cells. The active form (sulfenamide) binds covalently to the **H+/K+ ATPase (the final common pathway of acid secretion)**, causing **irreversible inhibition**. Because it blocks the final step, PPIs are the most potent acid-suppressing agents and are the **drugs of choice for Zollinger-Ellison Syndrome (ZES)**, where massive hypergastrinemia leads to refractory ulcers. **Analysis of Incorrect Options:** * **A. Cimetidine:** This is an **H2-receptor antagonist**. It competitively inhibits histamine-induced acid secretion. It is less potent than PPIs and does not act on the H+/K+ ATPase. It is also known for inhibiting Cytochrome P450 and causing anti-androgenic side effects (gynecomastia). * **B. Cisapride:** This is a **prokinetic agent** (5-HT4 agonist). It increases lower esophageal sphincter tone and promotes gastric emptying. It does not inhibit acid secretion and was largely withdrawn due to the risk of QT prolongation (Torsades de pointes). * **C. Glycopyrrolate:** This is an **anticholinergic (antimuscarinic)** drug. While it can reduce gastric secretions, its efficacy is low compared to PPIs, and it is primarily used as a pre-anesthetic medication to reduce salivary and respiratory secretions. **High-Yield Clinical Pearls for NEET-PG:** * **ZES Diagnosis:** Characterized by elevated serum gastrin (>1000 pg/mL) and a positive **Secretin Stimulation Test** (paradoxical rise in gastrin). * **PPI Administration:** Should be taken **30–60 minutes before meals** for maximum efficacy, as the pumps are most active post-prandially. * **Long-term PPI Risks:** Hypomagnesemia, Vitamin B12 deficiency, increased risk of *C. difficile* infections, and osteoporotic fractures (due to decreased calcium absorption).

Question 74: All of the following are used as antiemetics, EXCEPT:

A. Granisetron
B. Dolasetron
C. Palonosetron
D. Alosetron (Correct Answer)

Explanation: ### Explanation The correct answer is **D. Alosetron**. **1. Why Alosetron is the correct answer:** While Alosetron belongs to the same chemical class as the other options (**5-HT₃ receptor antagonists**), its clinical application is fundamentally different. Alosetron is used specifically for the treatment of **severe, diarrhea-predominant Irritable Bowel Syndrome (IBS-D)** in women who have not responded to conventional therapy. It works by blocking 5-HT₃ receptors on enteric neurons, thereby reducing GI motility, secretions, and visceral pain. It is **not** indicated for the treatment of nausea or vomiting. **2. Why the other options are incorrect:** * **A, B, and C (Granisetron, Dolasetron, Palonosetron):** These are potent antiemetics. They work by blocking 5-HT₃ receptors in the **Chemoreceptor Trigger Zone (CTZ)** and on vagal afferents in the GI tract. They are the "gold standard" for preventing chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Palonosetron:** It is a second-generation 5-HT₃ antagonist with a significantly **longer half-life** (~40 hours) and higher affinity. It is the only drug in this class approved for preventing **delayed** chemotherapy-induced emesis. * **Alosetron Warning:** It is associated with a rare but serious side effect: **Ischemic Colitis**. Due to this, its use is strictly regulated under a risk management program. * **Side Effects of Setrons:** Generally well-tolerated, but the most common side effects are **headache**, constipation, and **QT interval prolongation** (especially with Dolasetron). * **Mechanism Tip:** Remember, 5-HT₃ is the only serotonin receptor that is **ligand-gated ion channel** (the rest are G-protein coupled).

Question 75: A patient is taking 40 mg Famotidine OD, Sucralfate and Antacid tablets TDS. This treatment is irrational because of which of the following reasons?

A. Sucralfate decreases the absorption of famotidine.
B. Sucralfate increases the toxicity of famotidine.
C. Sucralfate decreases absorption of antacids.
D. Sucralfate polymerizes only when gastric pH is less than 4. (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Sucralfate polymerizes only when gastric pH is less than 4.** **Mechanism of Action:** Sucralfate is a complex of sulfated sucrose and aluminum hydroxide. It acts as a **cytoprotective agent** by forming a sticky, viscous paste that binds to the base of ulcer craters, creating a physical barrier against acid and pepsin. Crucially, this polymerization and activation process is **acid-dependent**. It requires an acidic environment (pH < 4) to undergo the necessary cross-linking. **Why the combination is irrational:** Both **Famotidine** (an H2-receptor antagonist) and **Antacids** increase the gastric pH (making it more alkaline). By raising the pH above 4, these drugs prevent the activation and polymerization of Sucralfate, thereby rendering it ineffective. Therefore, Sucralfate should ideally be taken on an empty stomach, at least 30 minutes to 1 hour before any acid-neutralizing or acid-suppressing agents [1]. --- ### Analysis of Incorrect Options: * **Option A & B:** While Sucralfate can adsorb many drugs (like tetracycline or digoxin) and decrease their absorption, there is no clinically significant pharmacokinetic interaction where it reduces the absorption or increases the toxicity of Famotidine specifically. * **Option C:** Sucralfate does not significantly interfere with the absorption of antacids; rather, the antacids interfere with the *efficacy* of Sucralfate by altering the pH [1]. --- ### NEET-PG High-Yield Pearls: * **Timing of Administration:** Sucralfate should be taken 1 hour before meals (on an empty stomach). * **Side Effects:** The most common side effect of Sucralfate is **constipation** (due to the aluminum content) [1]. * **Drug Interactions:** It can decrease the absorption of "DAN": **D**igoxin, **A**ntibiotics (Fluoroquinolones, Tetracyclines), and **N**aproxen/Phenytoin [1]. * **Clinical Use:** It is particularly useful for preventing stress ulcers in critically ill patients as it does not alter gastric pH, thus reducing the risk of nosocomial pneumonia compared to H2 blockers or PPIs.

Question 76: Which of the following stool softeners does not interfere with fat absorption?

A. Docusates (Correct Answer)
B. Phenolphthalein
C. Liquid paraffin
D. Castor oil

Explanation: **Explanation:** The correct answer is **Docusates (Option A)**. **1. Why Docusates are correct:** Docusates (Dioctyl sodium sulfosuccinate) are **anionic surfactants** that act as stool softeners. They work by lowering the surface tension of the stool, allowing water and lipids to penetrate the fecal mass. Unlike lubricant laxatives, docusates do not coat the intestinal mucosa or the food particles; therefore, they **do not interfere with the absorption of fat or fat-soluble vitamins** (A, D, E, K). **2. Why the other options are incorrect:** * **Liquid paraffin (Option C):** This is a lubricant laxative. It coats the fecal matter and the intestinal wall. Its primary clinical disadvantage is that it **interferes with the absorption of fat-soluble vitamins** and can lead to deficiency with chronic use. It can also cause lipid pneumonia if aspirated. * **Phenolphthalein (Option B):** This is a stimulant laxative (diphenylmethane derivative). While it acts on the colon to increase motility, it does not specifically target fat absorption; however, it is largely obsolete due to concerns regarding carcinogenicity. * **Castor oil (Option D):** This is a potent stimulant purgative. It is hydrolyzed in the small intestine to **ricinoleic acid**, which irritates the mucosa. While it doesn't "block" absorption like paraffin, it is not classified as a stool softener and is too harsh for routine use. **High-Yield Clinical Pearls for NEET-PG:** * **Docusate** is the drug of choice for patients where straining at stool must be avoided (e.g., post-myocardial infarction, post-surgery, or anal fissures). * **Liquid Paraffin** should never be taken at bedtime (risk of aspiration/lipid pneumonia) or used long-term (risk of malabsorption). * **Castor oil** is contraindicated in pregnancy as it may induce uterine contractions.

Question 77: All of the following are true regarding newer preparations of 5-ASA used to treat inflammatory bowel disease, EXCEPT:

A. Asacol is an enteric-coated form of mesalamine.
B. Pentasa uses ethylcellulose coating to allow water absorption.
C. 5-ASA agents act within 1 week. (Correct Answer)
D. A once-a-day formulation of mesalamine using the Multi-Matrix System is designed to release mesalamine in the colon.

Explanation: **Explanation:** **1. Why Option C is the correct answer (The Exception):** 5-Aminosalicylates (5-ASA), such as mesalamine, are the mainstay for inducing and maintaining remission in mild-to-moderate Ulcerative Colitis. However, they have a **slow onset of action**. Clinical improvement typically takes **2 to 4 weeks** to become evident. Expecting a full therapeutic effect within 1 week is clinically inaccurate, making this the "Except" statement. **2. Analysis of Incorrect Options:** * **Option A (Asacol):** This is a pH-dependent delayed-release formulation. It is coated with an **Eudragit-S resin** (enteric coating) that dissolves only when the luminal pH reaches $\geq$ 7, ensuring the drug is released specifically in the distal ileum and colon. [1, 2] * **Option B (Pentasa):** This formulation uses **microgranules coated with ethylcellulose**, which acts as a semi-permeable membrane. This allows water to enter the granules and slowly release mesalamine throughout the entire small intestine and colon. [1, 2] * **Option D (MMX Technology):** The **Multi-Matrix System (Lialda)** uses a lipophilic and hydrophilic matrix. This allows for a slow, uniform release of the drug throughout the entire length of the colon, facilitating **once-daily dosing**, which improves patient compliance. [2] **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** 5-ASA inhibits the production of secondary pro-inflammatory mediators (Leukotrienes and Prostaglandins) and interferes with NF-$\kappa$B signaling. [1] * **Site of Action:** 5-ASA acts **topically** on the diseased mucosa; it is not a systemic effect. * **Prodrugs:** Sulfasalazine, Olsalazine, and Balsalazide are prodrugs where 5-ASA is linked by an **azo-bond**, which is cleaved by **bacterial azoreductase** in the colon. [1] * **Side Effects:** Sulfasalazine is often poorly tolerated due to the **sulfapyridine** moiety (causes headache, dyspepsia, and male infertility). Newer 5-ASA preparations lack this moiety and are better tolerated.

Question 78: Which of the following drugs has been implicated in the causation of subacute myelo-optic neuropathy (SMON)?

A. Diloxanide furoate
B. Quiniodochlor (Correct Answer)
C. Emetine
D. Furazolidone

Explanation: **Explanation:** **Quiniodochlor (Iodoquinol)**, a halogenated hydroxyquinoline, is the correct answer. It was widely used as a luminal amoebicide until the 1970s when it was linked to an epidemic of **Subacute Myelo-Optic Neuropathy (SMON)**, particularly in Japan. * **Mechanism of Toxicity:** Prolonged use of high doses leads to neurotoxicity characterized by sensory and motor disturbances, muscle weakness, and **optic atrophy** leading to blindness. Due to this severe adverse effect, its use is now strictly restricted or banned in many countries. **Analysis of Incorrect Options:** * **Diloxanide furoate:** This is a highly effective luminal amoebicide and the drug of choice for asymptomatic cyst passers. It is generally well-tolerated; its primary side effects are flatulence and nausea, not neurotoxicity. * **Emetine:** An alkaloid derived from Ipecacuanha used for severe systemic amoebiasis. Its major toxicity is **cardiotoxicity** (hypotension, ECG changes, and arrhythmias), not SMON. * **Furazolidone:** A nitrofuran derivative used for giardiasis and bacterial enteritis. Key side effects include GI upset, hemolysis in G6PD deficiency, and a **disulfiram-like reaction** with alcohol. **High-Yield Clinical Pearls for NEET-PG:** * **SMON Triad:** Abdominal symptoms followed by dysesthesia (numbness/tingling) and visual impairment. * **Luminal Amoebicides:** Remember the "IQ" mnemonic for Halogenated Hydroxyquinolines: **I**odoquinol and **Q**uiniodochlor. * **Drug of Choice (DOC):** For asymptomatic intestinal amoebiasis, the DOC is **Diloxanide furoate** or **Paromomycin**. For hepatic/tissue amoebiasis, **Metronidazole** followed by a luminal agent is standard.

Question 79: What is the treatment for peptic ulcer disease?

A. Antacids
B. Ranitidine
C. Sucralfate
D. All of the above (Correct Answer)

Explanation: The treatment of Peptic Ulcer Disease (PUD) focuses on two primary goals: reducing gastric acidity and enhancing mucosal protection. The correct answer is **"All of the above"** because each option represents a distinct pharmacological class used in the management of PUD. ### **Explanation of Options:** 1. **Antacids (Option A):** These are weak bases (e.g., Aluminum hydroxide, Magnesium hydroxide) that chemically neutralize gastric HCl. They provide rapid symptomatic relief and reduce pepsin activity. 2. **Ranitidine (Option B):** This is an **H₂-receptor antagonist**. It competitively inhibits histamine at the H₂ receptors on gastric parietal cells, significantly reducing both basal and meal-stimulated acid secretion. 3. **Sucralfate (Option C):** This is a **mucosal protective agent**. In an acidic environment (pH < 4), it polymerizes into a sticky paste that binds to the ulcer base, forming a physical barrier against acid, pepsin, and bile. ### **Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** While all the above are used, **Proton Pump Inhibitors (PPIs)** like Omeprazole are currently the DOC for PUD due to superior efficacy and longer duration of action. * **H. pylori Eradication:** If the ulcer is associated with *H. pylori*, a "Triple Therapy" (PPI + Amoxicillin + Clarithromycin) is standard. * **Sucralfate Interaction:** It requires an acidic medium for activation; therefore, it should **not** be administered simultaneously with antacids or H₂ blockers. * **Side Effects:** Magnesium salts cause diarrhea, while Aluminum salts cause constipation (often combined to balance bowel effects). Ranitidine has a better safety profile than Cimetidine, which causes gynecomastia due to anti-androgenic effects.

Question 80: Which of the following drugs is used for the medical treatment of gallstones?

A. Clemastine fumarate
B. Mizolastine
C. Lovastatin
D. Ursodeoxycholic acid (Correct Answer)

Explanation: **Explanation:** **Ursodeoxycholic acid (UDCA)** is the correct answer. It is a naturally occurring bile acid used for the non-surgical dissolution of radiolucent cholesterol gallstones [2]. **Mechanism of Action:** UDCA works by reducing the secretion of cholesterol from the liver into the bile and decreasing the fractional absorption of dietary cholesterol in the intestines [1], [2]. This shifts the bile composition from "lithogenic" (stone-forming) to "non-lithogenic," leading to the gradual dissolution of existing cholesterol stones [3]. It is primarily indicated for patients with small (<15mm), radiolucent stones who have a functioning gallbladder but are unfit for surgery [2]. **Analysis of Incorrect Options:** * **Clemastine fumarate (A):** A first-generation H1-receptor antagonist (antihistamine) used for allergic rhinitis and urticaria. It has significant sedative and anticholinergic side effects. * **Mizolastine (B):** A second-generation, non-sedating H1-receptor antagonist used for allergic symptoms. * **Lovastatin (C):** An HMG-CoA reductase inhibitor (statin) used to treat hypercholesterolemia [4]. While it lowers systemic cholesterol, it is not used for the direct dissolution of gallstones. **NEET-PG High-Yield Pearls:** * **Prerequisite for UDCA:** The gallbladder must be **functional** (visualized on oral cholecystography) and stones must be **radiolucent** (pure cholesterol). Pigment stones do not respond to UDCA. * **Other uses of UDCA:** It is the first-line treatment for **Primary Biliary Cholangitis (PBC)**, where it slows disease progression. * **Side Effects:** Generally well-tolerated, but can cause diarrhea and, rarely, hepatotoxicity. * **Chenodeoxycholic acid** is another bile acid used for stones but is less preferred than UDCA due to higher incidences of diarrhea and hepatotoxicity.

Practice by Chapter

Acid-Peptic Disease Therapeutics

Practice Questions

Proton Pump Inhibitors

Practice Questions

H2 Receptor Antagonists

Practice Questions

Antacids and Mucosal Protectants

Practice Questions

Antiemetics

Practice Questions

Prokinetic Agents

Practice Questions

Laxatives and Purging Agents

Practice Questions

Antidiarrheal Drugs

Practice Questions

Drugs for Inflammatory Bowel Disease

Practice Questions

Pancreatic Enzyme Supplements

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free